Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | furin-1 (S08 family) | 0.0623 | 0.3233 | 0.3233 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.089 | 0.5428 | 0.4865 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Echinococcus granulosus | furin | 0.1448 | 1 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.092 | 0.5668 | 0.7068 |
Schistosoma mansoni | hypothetical protein | 0.0297 | 0.0558 | 0.0558 |
Echinococcus multilocularis | 0.1151 | 0.7565 | 1 | |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.1448 | 1 | 1 |
Brugia malayi | celfurPC protein | 0.1151 | 0.7565 | 0.4378 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.089 | 0.5428 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1448 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0557 | 0.2695 | 0.1796 |
Schistosoma mansoni | intracisternal A-particle retropepsin (A02 family) | 0.1258 | 0.8446 | 0.8446 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0528 | 0.2455 | 1 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.1448 | 1 | 1 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.092 | 0.5668 | 0.5135 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.089 | 0.5428 | 0.6696 |
Schistosoma mansoni | subfamily S8B non-peptidase homologue (S08 family) | 0.0362 | 0.1096 | 0.1096 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.089 | 0.5428 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0362 | 0.1096 | 0.1105 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 16 % | Antimalarial activity schizonticidal against Plasmodium falciparum 3D7 infected erythrocytes at 0.05 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 33 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 0.09 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 41 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 0.19 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 75 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 0.39 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 95 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 0.78 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 100 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 10 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 100 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 5 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 100 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 2.5 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Inhibition (functional) | = 100 % | Antimalarial schizonticidal activity against Plasmodium falciparum 3D7 infected erythrocytes at 1.25 ug/ml after 30-39 hrs | ChEMBL. | 19095455 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.